Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
- 1 August 1997
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1333 (1) , F51-F71
- https://doi.org/10.1016/s0304-419x(97)00011-5
Abstract
No abstract availableThis publication has 110 references indexed in Scilit:
- Interaction of Transforming Growth Factor-β Receptor I with Farnesyl-protein Transferase-α in Yeast and Mammalian CellsPublished by Elsevier ,1996
- Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RASScience, 1996
- Mutagenesis of Active Site Residues in Type I Dehydroquinase from Escherichia coliPublished by Elsevier ,1995
- CAAX Peptidomimetic FTI-244 Decreases Platelet-Derived Growth Factor Receptor Tyrosine Phosphorylation Levels and Inhibits Stimulation of Phosphatidylinositol 3-Kinase but Not Mitogen-Activated Protein KinaseBiochemical and Biophysical Research Communications, 1995
- Two Distinct Raf Domains Mediate Interaction with RasJournal of Biological Chemistry, 1995
- Anti-Ras drugs come of ageCurrent Biology, 1993
- Predisposition to Neoplastic Transformation Caused by Gene Replacement of H- ras 1Science, 1993
- Triggering signaling cascades by receptor tyrosine kinasesTrends in Biochemical Sciences, 1992
- The GTPase superfamily: conserved structure and molecular mechanismNature, 1991
- Regulation of the mevalonate pathwayNature, 1990